GMP facility for innovative drugs (KFT-J10 / IGFL)

The GMP Facility LUMC is part of the department of Clinical Pharmacy & Toxicology of the LUMC, and facilitates development and production of Advanced Therapy Medicinal Products (ATMPs) and chemical (peptide) synthesis. These advanced products for experimental clinical use include cellular products, some of which are gene modified, peptides and radiopharmaceutical products.

GMP production facility at Leiden University Medical Center, the Netherlands (short)

We accelerate the transition of product candidates from discovery to the clinic. We offer expertise in translational drug development and manufacturing of new innovative drugs for clinical use. We offer manufacturing services of Active Pharmaceutical Ingredients (API) and finished Investigational Medicinal Products (IMP) under Good Manufacturing Practices (GMP). Final drug product will be delivered together with  documentation needed for approval by regulatory authorities. 

We support LUMC researchers to translate preclinical findings to the clinic. We also offer our services to other (academic) hospitals and to companies. 

Our main expertise: